Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Active Rheumatoid Arthritis Clear all
Terminated Phase 2 Interventional Results available

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

NCT00655824
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ofatumumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

NCT00753454
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy

NCT00106522
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

NCT01185353
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY3009104, Placebo, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

NCT03691909
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pasadena, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

NCT02683421
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 23, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT05516758
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Peresolimab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Results available

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055
View directory record Official record
Conditions
Rhematoid Arthritis
Interventions
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
60
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

NCT00424346
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
12
States / cities
Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT00889863
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
canakinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Jul 23, 2026, 3:32 AM EDT
Completed No phase listed Observational

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

NCT03810144
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Vectra MBDA Test
Genetic
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Annapolis, Maryland • Baltimore, Maryland • Catonsville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Trial of a Physical Activity Intervention for RA Fatigue

NCT01874977
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Pedometer, Educational materials, Step count goals
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

NCT02996500
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06650833, Placebo, Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Study Evaluating TMI-005 in Active Rheumatoid Arthritis

NCT00095342
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TMI-005
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
4
States / cities
Indianapolis, Indiana • Syracuse, New York • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

NCT00550446
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Adalimumab, CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
22
States / cities
Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Health Promotion and Wellness Program for Adults With Disabling Conditions

NCT01776034
View directory record Official record
Conditions
Stroke, Multiple Sclerosis, Rheumatoid Arthritis
Interventions
SystemCHANGE Group Lifestyle counseling, Phone Lifestyle Counseling
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

NCT02919475
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Tucson, Arizona • Upland, California • Clearwater, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

NCT00049751
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Apple Valley, California • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2006 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

NCT00626275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ADL5859, Naproxen, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Jul 23, 2026, 3:32 AM EDT